HYBIO(SZ:300199) Zheng Quan Zhi Xing·2025-08-21 09:14Core Viewpoint - Shenzhen Hanyu Pharmaceutical Co., Ltd. has received marketing authorization for its product Atosiban Acetate Injection from the Vietnam Ministry of Health, which is expected to enhance the company's international market presence and competitiveness [1][2]. Group 1: Drug Information - Drug Name: Atosiban Acetate Injection [1] - Registration Number: 690110326625 [1] - Specification: 5ml:37.5mg [1] - Manufacturer: Shenzhen Hanyu Pharmaceutical Co., Ltd. [1] - Validity of Approval: Until July 17, 2030 [1] Group 2: Drug Application - Atosiban is a competitive antagonist of oxytocin receptors, indicated for pregnant women with signs of preterm labor, aimed at delaying imminent preterm birth [1]. Group 3: Impact on the Company - The approval of Atosiban Acetate Injection is expected to enrich the company's overseas product pipeline and expand its international market [1]. - The company plans to actively promote the sales of this drug in overseas markets, enhancing its international brand influence and overall competitiveness [1].